BEIGENE LTD-ADR (BGNE) Stock Price, Quote, News and Overview
NASDAQ:BGNE - Nasdaq - US07725L1026 - ADR - Currency: USD
BGNE Quote, Performance and Key Statistics
184.71
+0.9 (+0.49%)
The current stock price of BGNE is 184.71 USD. In the past month the price decreased by -10.23%. In the past year, price increased by 11.69%.
BGNE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BGNE
Company Profile
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Company Info
BEIGENE LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY1-1108 KY
CEO: John V. Oyler
Employees: 10000
Company Website: https://www.beigene.com/
Investor Relations: https://ir.beigene.com
Phone: 13459494123
BEIGENE LTD-ADR / BGNE FAQ
What is the stock price of BEIGENE LTD-ADR today?
The current stock price of BGNE is 184.71 USD. The price increased by 0.49% in the last trading session.
What is the ticker symbol for BEIGENE LTD-ADR stock?
The exchange symbol of BEIGENE LTD-ADR is BGNE and it is listed on the Nasdaq exchange.
On which exchange is BGNE stock listed?
BGNE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BEIGENE LTD-ADR stock?
11 analysts have analysed BGNE and the average price target is 185.96 USD. This implies a price increase of 0.68% is expected in the next year compared to the current price of 184.71. Check the BEIGENE LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BEIGENE LTD-ADR worth?
BEIGENE LTD-ADR (BGNE) has a market capitalization of 19.67B USD. This makes BGNE a Large Cap stock.
How many employees does BEIGENE LTD-ADR have?
BEIGENE LTD-ADR (BGNE) currently has 10000 employees.
What are the support and resistance levels for BEIGENE LTD-ADR (BGNE) stock?
BEIGENE LTD-ADR (BGNE) has a support level at 180.06 and a resistance level at 184.72. Check the full technical report for a detailed analysis of BGNE support and resistance levels.
Is BEIGENE LTD-ADR (BGNE) expected to grow?
The Revenue of BEIGENE LTD-ADR (BGNE) is expected to grow by 52.03% in the next year. Check the estimates tab for more information on the BGNE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BEIGENE LTD-ADR (BGNE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BGNE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BGNE, evaluating the profitability, health, valuation and growth aspects
- BEIGENE LTD-ADR (BGNE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEIGENE LTD-ADR (BGNE) Sales and EPS estimates to see what analysts future expectations are.
- BEIGENE LTD-ADR (BGNE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEIGENE LTD-ADR (BGNE) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEIGENE LTD-ADR (BGNE) Stock Chart to make your own analysis
- BEIGENE LTD-ADR (BGNE) Latest news and press-releases to stay up to date.
Does BEIGENE LTD-ADR (BGNE) stock pay dividends?
BGNE does not pay a dividend.
What is the Price/Earnings (PE) ratio of BEIGENE LTD-ADR (BGNE)?
BEIGENE LTD-ADR (BGNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-49.45).
BGNE Technical Analysis
BGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BGNE. Both the profitability and financial health of BGNE have multiple concerns.
BGNE Financial Highlights
Over the last trailing twelve months BGNE reported a non-GAAP Earnings per Share(EPS) of -49.45. The EPS decreased by -457.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -26.99% | ||
| Debt/Equity | 0.31 |
BGNE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to BGNE. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 35.87% and a revenue growth 52.03% for BGNE